Differentiation is key for a biotech start-up or an academic asset to be noticed and stand-up on the busy field of oncology. Similarly, spotting ideal partnership candidates for pharma proves increasingly difficult. How to take R&D to partnership with pharma? What is the recipe for a successful partnership in a packed sector? How to anticipate the hurdles of sailing an overloaded boat?
| Speakers |
|---|
|
Pierre-Michel Bringer - Novartis |
|
Therese Liechtenstein - M Ventures |
|
Chris De Jonghe - Oncode Institute |
